Gerosynth Labs develops FDA‑accepted investigational oncology drugs for equine, canine, and feline cancers and offers Mytulin EQ, a phytochemical‑based equine supplement that supports immune function, cellular vitality, musculoskeletal strength, gastrointestinal balance, and mitochondrial health. By combining novel therapeutic pipelines with evidence‑based nutraceuticals, the company provides veterinarians and animal caretakers scientifically validated options to improve cancer outcomes and performance recovery across companion animals.
Funding
Funding not disclosed
Founders
Product
Problem
Veterinary patients—including horses, dogs, and cats—often lack effective, targeted therapies for cancer and comprehensive nutritional solutions that support immune function, cellular health, and performance recovery. Existing treatments can be limited in efficacy, and there is a shortage of scientifically formulated supplements that address musculoskeletal, gastrointestinal, and mitochondrial health in equine athletes.
Solution
Gerosynth Labs develops novel oncology therapeutics for companion animals and a next‑generation equine nutritional supplement, Mytulin EQ. The company has secured FDA Center for Veterinary Medicine acceptance of multiple Investigational New Animal Drug (INAD) filings, advancing candidate drugs toward market approval for equine, feline, and canine cancers. Mytulin EQ is formulated using proprietary phytochemical research to enhance immune health, cellular vitality, musculoskeletal strength, gastrointestinal balance, and mitochondrial function, thereby supporting recovery and performance in horses. By integrating advanced drug development pipelines with evidence‑based nutraceuticals, Gerosynth provides veterinarians and animal caretakers with scientifically validated options to improve health outcomes across species.
Target Audience
Primary customers are veterinary oncologists, equine veterinarians, and animal health professionals seeking advanced cancer therapies and performance‑enhancing supplements for horses, as well as horse owners and trainers focused on optimal health and recovery.
Features
- FDA‑accepted INAD filings for oncology candidates targeting equine, feline, and canine cancers
- Proprietary phytochemical formulation in Mytulin EQ that supports immune, cellular, musculoskeletal, gastrointestinal, and mitochondrial health
- Designed for performance recovery and longevity in high‑activity horses
- Focus on regenerative and cellular‑health therapeutics applicable to multiple veterinary species
- Integration of drug development and nutraceutical pipelines to streamline translational research